Post hoc analysis of the phase IIIb REALISTIC trial (930 patients with RA): at week 12, certolizumab pegol improved disease activity similarly regardless of high (≥180 kU/L) or lower rheumatoid factor and prior TNFi failure; placebo patients did not improve.
Secondary analysisn = 930
Smolen et al. Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial